See the DrugPatentWatch profile for Proleukin
Is Proleukin still protected by a patent?
Proleukin is the brand name for high-dose interleukin-2 (IL-2). Patents on older biologics like Proleukin typically expired long ago, and current competition is often driven by regulatory pathway eligibility and practical market factors rather than a single “still-active” Proleukin patent.
However, the exact answer depends on which “Proleukin patent” you mean (drug substance, formulation, manufacturing process, new dosing regimens, or later-life-cycle patents). With only the term “Proleukin patent” and no jurisdiction or patent number, it’s not possible to identify whether any specific Proleukin-related patent is currently in force.
Which patents are people usually referring to for Proleukin (IL-2)?
When searches mention “Proleukin patent,” they usually target one of these categories:
- Original composition-of-matter or early IL-2 related IP (often from the 1980s–1990s era).
- Manufacturing/process patents for producing recombinant IL-2.
- Later patents tied to specific formulations, stability, or administration methods.
- Life-cycle patents connected to new indications or dosing approaches.
If you can share the patent number, assignee, or the country/state you care about (e.g., US vs. EU), the determination of “in force vs. expired” becomes straightforward.
When did Proleukin’s exclusivity/patent protection typically end?
For biologics and older oncology drugs, the practical market “lock” usually ends after patent expiration plus any extensions, then competition follows through biosimilar/biologic pathways or supply entry.
Because “Proleukin” spans multiple potential IP assets and the timing differs by jurisdiction, you need at least one anchor detail (country or patent family) to calculate a reliable end date.
Why does the answer differ between the US and other countries?
Patent duration and extension rules vary by jurisdiction, and so do data exclusivity regimes. Even if a core patent expired in the US, another jurisdiction could have different remaining term for:
- specific process/formulation claims,
- secondary patents in the same family,
- or regulatory exclusivities.
What should I do to find the exact active Proleukin patents (if any)?
To get a precise, legally accurate answer, search by:
- Active ingredient: interleukin-2 (IL-2) / recombinant IL-2
- Brand: Proleukin
- Assignee (company name tied to the patent family)
- Jurisdiction (USPTO, EMA/EPO, etc.)
If you tell me the jurisdiction and either the patent number or the assignee, I can translate that into “expired/in force” and the likely clinical/commercial impact.
Are there biosimilars or alternatives to Proleukin that make patent questions less relevant?
Even after patent expiration, market access can still depend on:
- whether biosimilars are authorized for the same indications and dosing,
- manufacturing availability,
- reimbursement decisions,
- and clinician familiarity.
If you want, tell me your country and whether you care about availability, pricing, or regulatory status; I can focus on that angle rather than just the patent timeline.
What do you mean by “Proleukin patent”?
Reply with one detail and I’ll give a concrete answer:
1) Patent number (or link), or
2) Assignee/company name, or
3) Country/jurisdiction (US, UK, EU, etc.), or
4) The aspect: composition, formulation, manufacturing, or method of use.